SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Maximizing Israel-U.S. 
Research Advancement and Collaborative Leadership in 
Emerging Medical Technology Act of 2025’’ or the ‘‘MIR-
ACLE Medical Technology Act of 2025’’. 
SEC. 2. PROGRAM FOR FACILITATION AND COORDINATION 
OF UNITED STATES-ISRAEL EFFORTS ON THE 
DEVELOPMENT AND DELIVERY OF HEALTH 
CARE PRODUCTS AND SERVICES. 
(a) IN GENERAL.—Subject to the availability of ap-
propriations, the Secretary of Health and Human Serv-
ices, in consultation with the Secretary of Commerce, the 
Council for Technology and Innovation of the Centers for 
Medicare & Medicaid Services, and the Commissioner of 
Food and Drugs, shall carry out a program to facilitate 
and coordinate efforts between the United States and 
Israel to expand and enhance collaboration on— 
(1) the development of health care products and 
services; and 
(2) the delivery of such products and services to 
those in need. 
(b) PROGRAM COMPONENTS.—The program under 
subsection (a) shall include facilitation and coordination 
of efforts including each of the following: 
(1) RESEARCH AND DEVELOPMENT.— 
VerDate Sep 11 2014 
21:13 Feb 19, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H661.IH
H661
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(A) Joint research projects between United 
States and Israeli institutions and companies. 
(B) Promoting collaboration in areas such 
as medical device technology, pharmaceuticals 
(including biological products, genomics, and in-
novative digital health care solutions), and 
health care systems management, including a 
special focus on early-stage clinical trials. 
(C) With respect to biological products, 
supporting— 
(i) innovation; 
(ii) process optimization; and 
(iii) the development of advanced 
manufacturing techniques that can en-
hance productivity, reduce costs, and im-
prove product quality. 
(D) Work toward developing a framework 
for sharing health data for research purposes 
with the Ministry of Health of Israel. 
(2) INNOVATION AND START-UP ECOSYSTEM.— 
(A) Fostering collaboration between United 
States and Israeli start-up and other companies 
in the health care sector. 
(B) Facilitating innovative technology ac-
ceptance by the marketplace. 
VerDate Sep 11 2014 
21:13 Feb 19, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H661.IH
H661
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(C) Facilitating mechanisms for technology 
transfer and joint venture opportunities. 
(D) Supporting innovation hubs to accel-
erate the development and commercialization of 
United States health care technologies in the 
Israeli market, including by encouraging cyber-
security standards for sharing data, promoting 
patient privacy, and encouraging research. 
(3) REGULATORY HARMONIZATION AND INTEL-
LECTUAL
PROPERTY
PROTECTION.—Establishing 
joint efforts— 
(A) to ensure intellectual property protec-
tion; 
(B) to increase regulatory harmonization, 
including with respect to regulatory data pro-
tection for biological products; 
(C) to formulate plans for a commer-
cialization framework for medical device tech-
nologies; 
(D) to encourage a potential mutual rec-
ognition agreement for pharmaceutical good 
manufacturing Practices between the Food and 
Drug Administration and Israeli regulators; 
(E) to strengthen and reaffirm the con-
fidentiality commitment with the Food and 
VerDate Sep 11 2014 
21:13 Feb 19, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H661.IH
H661
kjohnson on DSK7ZCZBW3PROD with $$_JOB
Drug Administration and the Pharmaceutical 
Division, the Medical Devices Department, and 
the National Food Services and Nutrition Divi-
sion of the Ministry of Health of Israel; 
(F) to encourage Israel’s participation in 
regulatory harmonization and cooperation orga-
nizations; and 
(G) to expand international collaboration 
under Project Orbis for concurrent submission 
and review of oncology products. 
(4) HEALTH CARE SYSTEM STRENGTHENING.— 
Facilitating the sharing of best practices, knowledge, 
and skills in areas such as clinical care and health 
care management. 
(5) TELEMEDICINE AND DIGITAL HEALTH CO-
OPERATION.—Establishing initiatives— 
(A) to enhance telemedicine infrastructure; 
(B) to promote interoperability between 
United States and Israeli health care systems; 
and 
(C) to facilitate collaboration on digital 
health technologies, data analytics, and cyberse-
curity. 
(6) DISEASE
PREVENTION
INITIATIVES.—Col-
laborating in disease prevention, including joint ef-
VerDate Sep 11 2014 
21:13 Feb 19, 2025
Jkt 059200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H661.IH
H661
kjohnson on DSK7ZCZBW3PROD with $$_JOB
forts to combat infectious diseases, develop vaccines, 
and share epidemiological data. 
(7) BIOLOGICAL PRODUCT MANUFACTURING.— 
(A) Promoting biological product manufac-
turing. 
(B) Establishing joint manufacturing fa-
cilities for biological products in facilities in the 
United States that leverage the strengths and 
expertise of both countries. 
(C) Pursuing accelerated development of 
life-saving treatments and new sources of nutri-
tion that are both healthier and more available 
at an affordable cost. 
(D) Workforce training and skill develop-
ment, including promoting exchange programs 
and training initiatives to develop a skilled 
workforce in biological product manufacturing. 
(E) Supply chain resilience through stra-
tegic collaboration to identify and develop con-
tingency plans to mitigate biological product 
supply disruptions. 
(F) Facilitating public-private partnerships 
to support the development and scale-up of bio-
logical product manufacturing capabilities. 
VerDate Sep 11 2014 
21:13 Feb 19, 2025
Jkt 059200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H661.IH
H661
kjohnson on DSK7ZCZBW3PROD with $$_JOB
(c) UNITED STATES-ISRAEL HEALTH CARE COL-
LABORATION CENTER.—In carrying out the program 
under subsection (a), the Secretary of Health and Human 
Services may establish a joint United States-Israel Health 
Care Collaboration Center in the United States leveraging 
the experience, knowledge, and expertise of institutions of 
higher education, national laboratories, entities in the pri-
vate sector, and others in the development and delivery 
of health care products and services. 
(d) COMMENCEMENT
OF IMPLEMENTATION.—Not 
later than 6 months after the date of enactment of this 
Act, the Secretary of Health and Human Services shall 
commence implementation of the program under this sec-
tion. 
(e) AUTHORIZATION OF APPROPRIATIONS.—To carry 
out this Act, there is authorized to be appropriated 
$8,000,000 for each of fiscal years 2026 through 2030. 
Æ 
VerDate Sep 11 2014 
21:13 Feb 19, 2025
Jkt 059200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6301
E:\BILLS\H661.IH
H661
kjohnson on DSK7ZCZBW3PROD with $$_JOB